4.6 Review

NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment

期刊

DIABETES & METABOLISM
卷 47, 期 2, 页码 -

出版社

MASSON EDITEUR
DOI: 10.1016/j.diabet.2020.101215

关键词

Arrhythmias; CVD; Heart disease; NAFLD; Non-alcoholic fatty liver disease

资金

  1. School of Medicine, University of Verona, Verona, Italy
  2. Southampton NIHR Biomedical Research Centre in Southampton, UK [IS-BRC-20004]

向作者/读者索取更多资源

NAFLD is strongly associated with an increased risk of cardiovascular events and other cardiac complications, independently of traditional CVD risk factors. The risk of CVD and other cardiac/arrhythmic complications parallels the severity of NAFLD, with multiple underlying mechanisms likely contributing to this increased risk.
Background and aim. - Non-alcoholic fatty liver disease (NAFLD), affecting up to around 30% of the world's adult population, causes considerable liver-related and extrahepatic morbidity and mortality. Strong evidence indicates that NAFLD (especially its more severe forms) is associated with a greater risk of all-cause mortality, and the predominant cause of mortality in this patient population is cardiovascular disease (CVD). This narrative review aims to discuss the strong association between NAFLD and increased risk of cardiovascular, cardiac and arrhythmic complications. Also discussed are the putative mechanisms linking NAFLD to CVD and other cardiac/arrhythmic complications, with a brief summary of CVD risk prediction/stratification and management of the increased CVD risk observed in patients with NAFLD. Results. - NAFLD is associated with an increased risk of CVD events and other cardiac complications (left ventricular hypertrophy, valvular calcification, certain arrhythmias) independently of traditional CVD risk factors. The magnitude of risk of CVD and other cardiac/arrhythmic complications parallels the severity of NAFLD (especially liver fibrosis severity). There are most likely multiple underlying mechanisms through which NAFLD may increase risk of CVD and cardiac/arrhythmic complications. Indeed, NAFLD exacerbates hepatic and systemic insulin resistance, promotes atherogenic dyslipidae-mia, induces hypertension, and triggers synthesis of proatherogenic, procoagulant and proinflammatory mediators that may contribute to the development of CVD and other cardiac/arrhythmic complications. Conclusion. - Careful assessment of CVD risk is mandatory in patients with NAFLD for primary prevention of CVD, together with pharmacological treatment for coexisting CVD risk factors. (C) 2020 Elsevier Masson SAS. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据